Actinogen Medical is a biotechnology company that is listed on ASX and specializes in developing innovative therapies for neurological diseases such as those associated with dysregulated brain cortisol. The company's flagship product is Xanamem® which is designed to decrease the production of intracellular cortisol, commonly known as the stress hormone through the inhibition of the 11β-HSD1 enzyme present in the brain.